KPV is proof that a peptide does not need to be big to be powerful. It is just three amino acids, yet it carries the full anti-inflammatory punch of a much larger hormone, and it has a rare talent: it concentrates itself exactly where inflammation is worst. That self-targeting ability, combined with the fact that it works orally, has made KPV one of the most interesting compounds in gut and inflammation research.
What KPV is
KPV is a tripeptide made of lysine, proline, and valine. It is the tail end (residues 11 to 13) of alpha-melanocyte-stimulating hormone (alpha-MSH), a hormone the body uses to regulate inflammation. Researchers found that nearly all of alpha-MSH’s anti-inflammatory power lives in this tiny fragment, and that KPV keeps that power while dropping the parent hormone’s other effects, including the pigmentation signalling. The result is a clean, focused anti-inflammatory compound without the hormonal baggage.
What the research shows
The most compelling KPV research centers on the gut. A landmark study by Dalmasso and colleagues, published in Gastroenterology in 2008, showed that KPV is actively transported into intestinal cells through a transporter called PepT1, and that once inside it reduced intestinal inflammation. The detail that makes this remarkable is that PepT1 ramps up during gut inflammation, so KPV naturally accumulates in exactly the inflamed tissue that needs it. The authors described KPV as a promising option for inflammatory bowel disease.
KPV’s reach extends beyond the gut. Research has documented anti-inflammatory effects in skin and wound-healing models, and the compound also shows antimicrobial activity against organisms like S. aureus and C. albicans in lab assays. A practical standout is that KPV is small and stable enough to survive digestion and work orally, which most peptides cannot do, making it especially attractive for gut-focused research.
How it works
KPV’s main mechanism is inhibition of NF-κB, the master switch that turns on inflammatory genes. When NF-κB is active, it drives the production of inflammatory messengers like TNF-alpha, IL-1beta, and IL-6. By dampening that switch inside cells, KPV lowers the whole inflammatory cascade at its source rather than chasing individual symptoms. It does this through a receptor-independent route, which is why it avoids the pigmentation and other effects tied to alpha-MSH’s receptor activity. Combined with the PepT1 transporter that delivers it straight into inflamed gut cells, KPV is essentially a self-guided anti-inflammatory.
Quick facts
| KPV | |
|---|---|
| Type | Tripeptide (Lys-Pro-Val) |
| Derived from | The C-terminal fragment of alpha-MSH |
| Best known for | Calming inflammation, especially in the gut |
| Key mechanism | NF-κB inhibition (lowers TNF-alpha, IL-1beta, IL-6) |
| Standout trait | Self-targets inflamed gut tissue via PepT1; works orally |
| Also studied for | Skin and wound healing, antimicrobial activity |
| Form | Lyophilized powder, reconstituted before use |
What to look for when buying
For an anti-inflammatory peptide, purity matters because contaminants work directly against the goal. Look for a Certificate of Analysis (COA) from third-party testing and an HPLC-MS purity figure of 99% or higher. Every batch of Marek Pharma’s KPV is HPLC-MS tested with a COA, lyophilized for stability, and ships from within Canada.
References
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 2008.
- Getting SJ, et al. Anti-inflammatory activity of the alpha-MSH fragment KPV, 2003.
- Catania A, et al. Melanocortin peptides and the control of inflammation (alpha-MSH and KPV anti-inflammatory research).
For laboratory and research use only.